SectorPharmaceutical
Established Date11/01/2018
Listing Date10/02/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees3
Fiscal Year Ends31/12
Security TypeCommon stock
Office address2223 Avenida de la Playa, #208, La Jolla, CA 92037
Business
IntroductionGRI Bio, Inc., was incorporated under the laws of the State of Delaware on January 11, 2018. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for disorders associated with the immune response. Its lead product candidate, GRI-0621, is an oral inhibitor of iNKT cells under development for the treatment of idiopathic pulmonary fibrosis and other serious inflammatory and fibrotic diseases.
